Sangamo Therapeutics Inc (NASDAQ:SGMO) shares fell 9.6% during trading on Monday . The company traded as low as $17.80 and last traded at $17.90. 3,486,607 shares were traded during trading, an increase of 58% from the average session volume of 2,207,694 shares. The stock had previously closed at $19.80.
A number of brokerages have recently commented on SGMO. BidaskClub raised Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 17th. ValuEngine upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Jefferies Group reiterated a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Wedbush reiterated a “hold” rating and set a $8.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 13th. Finally, Piper Jaffray set a $25.00 price objective on Sangamo Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $20.83.
The company has a debt-to-equity ratio of 0.13, a current ratio of 5.54 and a quick ratio of 5.54. The company has a market cap of $1,709.51, a PE ratio of -25.57 and a beta of 2.80.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. Sangamo Therapeutics had a negative return on equity of 31.44% and a negative net margin of 149.23%. The company had revenue of $13.08 million for the quarter, compared to analyst estimates of $11.10 million. During the same period in the previous year, the company posted ($0.14) EPS. The firm’s revenue for the quarter was up 46.6% compared to the same quarter last year. equities analysts expect that Sangamo Therapeutics Inc will post -0.15 EPS for the current year.
In other Sangamo Therapeutics news, Director Steven J. Mento sold 11,520 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $20.59, for a total value of $237,196.80. Following the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $102,950. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $20.59, for a total value of $308,850.00. Following the completion of the transaction, the vice president now owns 29,625 shares in the company, valued at $609,978.75. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 89,896 shares of company stock worth $1,952,212. 5.50% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Xact Kapitalforvaltning AB bought a new position in Sangamo Therapeutics in the 4th quarter worth about $175,000. MetLife Investment Advisors LLC bought a new position in Sangamo Therapeutics in the 4th quarter worth about $643,000. Macquarie Group Ltd. increased its stake in Sangamo Therapeutics by 1,016.7% in the 4th quarter. Macquarie Group Ltd. now owns 20,100 shares of the biopharmaceutical company’s stock worth $330,000 after acquiring an additional 18,300 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in Sangamo Therapeutics by 70.0% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 19,189 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 7,900 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. bought a new position in Sangamo Therapeutics in the 4th quarter worth about $707,000. Institutional investors and hedge funds own 64.69% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Sangamo Therapeutics (SGMO) Trading Down 9.6%” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at www.tickerreport.com/banking-finance/3362846/sangamo-therapeutics-sgmo-trading-down-9-6.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.